China Respiratory Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

China Respiratory Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The China respiratory devices market is expected to register a CAGR of 12.5% over the forecast period.

With collective measures, scientific approaches, and public awareness, China dealt with the first wave of the COVID-19 pandemic in 2020. The second pandemic wave has undoubtedly resulted in a regional shortage of medical oxygen. For instance, in May 2021, China exported over 26,000 ventilators and oxygen concentrators, over 15,000 patient monitors, and nearly 3,800 tons of medicinal materials and medicines to India. Chinese companies received Indian orders for over 70,000 oxygen concentrators. Such a surge in demand drove the growth of the market. However, the market lost some traction as COVID-19 cases declined in the first three quarters of the year 2022 as the COVID-19 pandemic accelerated the use of respiratory devices. However, with the re-elevation of COVID-19 cases in China, the demand for respiratory devices is expected to create lucrative opportunities for the growth of the China respiratory device market in the studied period.

The major driving factors include the high prevalence of respiratory diseases in China, the continuation of economic and demographic trends, technological advancements, and increasing applications in-home care settings. For instance, as per an article published by the National Library of Medicine, in October 2021, COPD remains an important public health problem in China. Effective prevention and control measures are likely to strengthen to raise the standard of living for chronic obstructive pulmonary disease (COPD) patients and lower the number of COPD-related premature deaths among the Chinese population. So, there is a high chance of adopting sophisticated respiratory devices within the population which will lead to market growth in China. Furthermore, the study published by BMC Pulmonary Medicine, in March 2022, supports the fact that there is good agreement and reproducibility between the measurements from the portable and traditional respiratory devices. A trustworthy tool for screening and diagnosing chronic airway diseases in primary care settings is the portable spirometer. Such a study to evaluate the effectiveness of the devices in China is expected to open up enormous opportunities for market participants and accelerate market growth.

Additionally, the increasing initiatives, product launches, and strategies by market players in China are also expected to contribute to the market's growth. For instance, in December 2021, Aerogen Pharma and Nuance Pharma signed an agreement to join forces in Greater China to develop a superior, non-invasive approach to the treatment of Respiratory Distress Syndrome, a life-threatening condition of preterm infants associated with long-term lung health issues in survivors. Also, in July 2022, a group of chronic obstructive pulmonary disease (COPD) patients in China underwent surgery using Broncus Medical’s InterVapor system, the device’s first use in the country since its approval by Chinese regulators in March 2022. Such development is expected to drive the growth of the market over the forecast period.

Hence, as to the factors such as the high prevalence of respiratory diseases in China, the continuation of economic and demographic trends, technological advancements, and increasing applications in-home care settings, China's respiratory devices market is anticipated to grow over the forecast period. However, the high cost associated with respiratory devices is likely to restrain the market growth.

Pulse oximetry is a noninvasive method for monitoring a person's oxygen saturation. This can be a useful tool in the management of chronic obstructive pulmonary disease (COPD) and other lung conditions such as asthma, emphysema, and bronchitis. Furthermore, it can also be used to assess shortness of breath, lung function before surgery, and the effect of medication. The pulse oximeter is used in the management of COPD, which is likely to be a promoting factor for market growth. For instance, as per the article published by the International Journal of Chronic Obstructive Pulmonary Disease, in September 2022, the prevalence of COPD in China was estimated as 13.7%, equating to approximately 99.9 million patients with COPD. Thus, with the increase in respiratory disease, the demand for pulse oximeters has increased, driving the growth of the market.

Additionally, the increasing initiatives, product launches, and strategies by the government and market players in China are also expected to contribute to the market's growth. For instance, in October 2022, GX Foundation launched a second phase of pulse oximeters distribution throughout the Hong Kong community. GX partnered with the Collaborating Centre for Oxford University and CUHK for Disaster and Medical Humanitarian Response (CCOUC) to distribute pulse oximeters to 20 organizations in total across the city. This enabled caregivers to provide home-based monitoring of elderly people and COVID-19 patients, strengthen the independence and effectiveness of home-based care, and alleviate the burden on hospitals during difficult times. Such an initiative is expected to drive the growth of the market over the forecast period.

Oxygen concentrators are used to provide oxygen therapy to people that require greater oxygen concentrations than the levels of ambient air. The oxygen concentrators segment has been fuelled by recent technological advancements and increased respiratory diseases cases such as asthma, emphysema, bronchitis, and COPD in China. For instance, according to an article published by BioMed Central Ltd in April 2022, moderate-to-severe airflow obstruction, more symptoms, and a high risk of exacerbations are prevalent among patients diagnosed with COPD in China. Thus, with an increase in COPD cases, the need for oxygen concentrator increases, driving the growth of the market.

Governments and key players are manufacturing and launching marks, which is expected to drive the segment. For instance, in March 2022, Belluscura signed a three-year manufacturing agreement for its X-PLO2r portable oxygen concentrator with InnoMax Medical Technology in China. Such development is expected to drive the growth of the market in China over the forecast period.

The China respiratory devices market is moderately concentrated due to the presence of companies operating globally and regionally. The well-known players include Drägerwerk AG & Co. KGaA, Teleflex Incorporated, Fisher & Paykel Healthcare Ltd, General Electric Company (GE Healthcare), and Nanjing Superstar Medical Equipment Co., Ltd, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support